Imiquimod
- Generic Name
- Imiquimod
- Brand Names
- Aldara, Vyloma, Zyclara
- Drug Type
- Small Molecule
- Chemical Formula
- C14H16N4
- CAS Number
- 99011-02-6
- Unique Ingredient Identifier
- P1QW714R7M
- Background
Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and cont...
- Indication
For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
- Associated Conditions
- Actinic Keratoses of the face, Actinic Keratoses of the scalp, Condylomata Acuminata, Herpes Simplex Infections, Molluscum Contagiosum, Superficial Basal Cell Carcinoma
- Associated Therapies
- -
Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated With Imiquimod
- Conditions
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Barretos Cancer Hospital
- Target Recruit Count
- 96
- Registration Number
- NCT06356012
Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides
- Conditions
- Interventions
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 25
- Registration Number
- NCT05838599
- Locations
- 🇺🇸
Northwestern University Department of Dermatology, Chicago, Illinois, United States
Gene and Protein Expression Profiles After Treatment of Actinic Keratoses
- Conditions
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Ismail Gögenur
- Target Recruit Count
- 48
- Registration Number
- NCT05740969
- Locations
- 🇩🇰
Zealand University Hospital, Roskilde, Region Sjælland, Denmark
Coadministration of GA2 Sporozoites With Adjuvants
- Conditions
- Interventions
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 45
- Registration Number
- NCT05468606
- Locations
- 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment
- Conditions
- Interventions
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Catharina Ziekenhuis Eindhoven
- Target Recruit Count
- 410
- Registration Number
- NCT05405270
- Locations
- 🇳🇱
Máxima MC, Veldhoven, Netherlands
🇳🇱Isala, Zwolle, Netherlands
🇳🇱HagaZiekenhuis, Den Haag, Netherlands
Efficacy of Tazarotene in Treatment of Verruca Plana
- Conditions
- Interventions
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- Zagazig University
- Target Recruit Count
- 80
- Registration Number
- NCT05314127
- Locations
- 🇪🇬
Dermatology department, Zagazig University Hospitals, Faculty of Medicine, Zagazig University, Zagazig, Select Region, Egypt
Comparing Immune Responses to Topical Imiquimod
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 6
- Registration Number
- NCT04809662
- Locations
- 🇺🇸
University of California Davis, Sacramento, California, United States
A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma
- First Posted Date
- 2018-05-23
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Melanoma Institute Australia
- Target Recruit Count
- 20
- Registration Number
- NCT03534947
- Locations
- 🇦🇺
Melanoma Institute Australia, North Sydney, New South Wales, Australia
H5N1 With or Without Topical Aldara in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2020-02-24
- Target Recruit Count
- 50
- Registration Number
- NCT03472976
- Locations
- 🇺🇸
Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
- Conditions
- Interventions
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 7
- Registration Number
- NCT03276832
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.